Nasal vaccine or monoclonal therapy: Which is winning weapon against SARS-CoV-2 variants in 2022?
J Glob Health
.
2022 May 14:12:03023.
doi: 10.7189/jogh.12.03023.
Authors
Lorenzo Lo Muzio
,
Francesca Spirito
PMID:
35567581
PMCID:
PMC9107288
DOI:
10.7189/jogh.12.03023
No abstract available
MeSH terms
COVID-19 Vaccines
COVID-19* / prevention & control
Humans
SARS-CoV-2
Vaccines*
Substances
COVID-19 Vaccines
Vaccines
Supplementary concepts
SARS-CoV-2 variants